Olivia has developed expertise across a range of therapeutics areas over the course of 7+ years of experience in life sciences research and consulting, but she has a specific interest in rare diseases, immunology, and ophthalmology. In particular, she has a passion for supporting clients with highly innovative technology platforms in the development and commercialization of their therapies for patients with significant unmet need. During her time at ClearView, Olivia has assisted a wide array of clients, ranging from leading biopharmaceutical companies to early-stage biotechs, in addressing their highest-priority strategic issues. Through this diversity of experience, Olivia has a demonstrated track record of ensuring commercial, clinical, and scientific factors are effectively considered to address her clients’ strategic questions.
While her historical experience spans a broad range of project types, Olivia focuses on commercialization strategy, including new product planning, portfolio prioritization, M&A and due diligence support, and strategic launch planning. Olivia received her B.A. in Economics and a Secondary Field in Chemistry from Harvard University.
Debbi Amanti Belanger
Seth Berman
Klaus Bredl
Steven Chao
Rishi Dalsania
Kim Goh
Ketan Kapadia
Philip Kenner
Stuart MacGregor
David McClain
Richard Mynahan
Kevin Richard
Mike Rizzo
Bill Shew
Ryan Tubman
Sam Ulin
Debbie Zhuang
Sidnee Pinho
Kristine Hyde
Jim Caruso
Steve Rubman
Lainey Miller
Brian Gibbs
Jonathan Betts
Dean Griffiths
Jonathan Hodgson
Slater Hurst
Dave Konciak
Charles Mathews
Rohit Kumar
Mike Roy
Beko Binder
Jessica Berard
Peter Goldman
Maneesh Gujrati
Austin Hubbert
Jonny Juliano
Owen Im
Andrew Kang
Patrick Kuettner
Joanna Lee
Alexander Lehrman
Alec Marchuk
Matthew Murphy
Mike Murray
Soyeon Park
Olivia Piccione
Matthew Pfister
Kai-Ming Pu
Sarah Stapleton
Kelsey Yardumian
Vini De Nadai